CAMBRIDGE TECHNOLOGIES LLC SBIR Phase I Award, August 2018

Influenza virus causes significant economic losses to the swine industry due to disease and decreased growth rates. Additionally, swine influenza viruses are zoonotic and represent a threat to public health. Both inactivated and live swine influenza virus vaccines are commercially available but are generally considered to lack efficacy to genetically diverse viruses circulating in the field. Here we will develop an influenza virus vaccine using a fundamentally different approach compared to currently licensed products. We anticipate that this vaccine will be efficacious to genetically diverse challenge viruses and stimulate effective, broad protection in growing pigs.